All In Biotech

Drug Trial Radar · NCT00867516

Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis

A Study to Determine the Safety, Efficacy, and Pharmacokinetics of 80,160 and 320mg ALD518 Versus Placebo Administered as Multiple IV Infusions to Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate

Last checked: Nov 20, 2026Latest source record: Jul 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 127 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

127

Actual

Start

Oct 2008

Primary completion

Jun 2009

Study completion Dec 2009

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Mar 23, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and efficacy of ALD518 in three different doses in patients who have not had an adequate response to methotrexate.

Conditions

  • Arthritis, Rheumatoid

Interventions

  • ALD518Biological

    Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8

  • Infusion without ALD518'Biological

    250 cc Normal saline IV over one hour Weeks 1 and 8.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of AEs and SAEs during the studyTime frame: During entire length of study

Locations

26 sites in 6 countries. Site status is shown where the registry gives one.

  • K-W Musculoskeletal Research, Inc.

    Kitchener, Ontario, Canada

  • Rheumatology Research Associates

    Ottawa, Ontario, Canada

  • V. Tsitlanadze Scientific Practical Centre of Rheumatology

    Tbilisi, Georgia

  • Medulla Chemotherapy and Immunotherapy Clinic

    Tbilisi, Georgia

  • St. John's Medical College Hospital

    Bangalore, India

  • Krishna Institute of Medical Sciences Ltd.

    Secunderabad, India

  • Chanre Rheumatology and Immunology Center and Research

    Malleshwaram, Bangalore, India

  • KLE Society Hospital and Medical Research Centre

    Nehru Nagar, Belgaum, India

  • Sushrut Hospital, Research Centre & Post Graduate Institute of Orthopaedics

    Ramadaspeth, Nagpur, India

  • Miriada Center Private Clinic of Professor Sierakowski

    Bialystok, Poland

  • Nonpublic Centre of Medical Care Reumed

    Lublin, Poland

  • NOVAMED - Medical Center of Poznan

    Poznan, Poland

  • Provincional Rheumatological Complex named after Dr Jadwiga Titz-Kosko

    Sopot, Poland

  • Szezecin Clinic of Rheumatology and Internal Diseases

    Szczecin, Poland

  • Regional Clinical Hospital of War Veterans

    Kemerovo, Russia

  • Institute of Clinical and Experimental Lymphology

    Novosibirsk, Russia

  • Ryazan Regional Clinical Cardiologic Dispensary

    Ryazan, Russia

  • Saint Petersburg Medical Academy of Postgraduate Study

    Saint Petersburg, Russia

  • Saint-Petersburg State Medical Academy named after I. I. Mechnikov

    Saint Petersburg, Russia

  • City Hospital #26

    Saint Petersburg, Russia

  • Regional War Veterans' Hospital

    Saratov, Russia

  • Tomsk Regional Clinical Hospital

    Tomsk, Russia

  • Tula Regional Clinical Hospital

    Tula, Russia

  • Clinical Hospital of Emergency Care named after N.V. Solovyev

    Yaroslavl, Russia

  • Institute of Rheumatology

    Belgrade, Serbia

  • Institute for Rehabilitation and Treatment Niska Banja

    Niška Banja, Serbia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.